Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

The change most people with asthma have not heard about

Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

If you have mild asthma and carry only a blue reliever inhaler, the global guidance on how to treat you changed in 2019, and a great deal of material written before then is now out of date.

The reason for the change is uncomfortable: people with mild asthma, using their reliever exactly as told, were having severe attacks and some were dying.

Related pages: Asthma

The bottom line

What we know
  • Short-acting reliever-only treatment is no longer recommended for adolescents and adults.
  • Airway inflammation is present even in mild and intermittent asthma.
  • All adolescents and adults should have inhaled corticosteroid in their treatment.
  • As-needed ICS-formoterol reduces severe attacks substantially compared with reliever alone.
What is still open
  • How quickly practice is actually changing in different countries.
  • How best to apply this approach to younger children, where the evidence differs.

The story, step by step

  1. 1. The old model ()
  2. 2. What was wrong ()
  3. 3. The change ()
  4. 4. The two tracks ()
  5. 5. What to ask ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

Reliever for mild, preventer for severe

Review of many studies

What happens

For decades, asthma treatment was graded by how often symptoms occurred.

What the research shows

  • Mild or intermittent asthma: a short-acting beta-agonist, SABA, such as albuterol or salbutamol, used when needed. The blue inhaler.
  • More frequent symptoms: add a daily inhaled corticosteroid preventer.
  • The logic was that someone with occasional symptoms had occasional narrowing, and relieving it when it happened was sufficient.
  • Relievers work: they relax airway muscle within minutes and the relief is real and immediate.
  • What they do not do is touch the inflammation underneath, and that turned out to be the problem.

Why it matters

The old approach treated the symptom precisely and left the disease untouched, which felt fine until it did not.

What's still uncertain

  • The approach worked well enough for most people most of the time, which is why it persisted.

Read more

Next: What was wrong

Part 2 of 5

Mild asthma is not safe asthma

Review of many studies

What happens

The evidence that changed the guidance came from looking at who was actually dying.

What the research shows

  • A substantial proportion of asthma deaths occur in people classified as having mild asthma.
  • Airway inflammation is present even when symptoms are infrequent. Biopsy studies have shown this directly.
  • Frequent reliever use is a marker of risk: using three or more reliever canisters a year is associated with a higher risk of severe attacks, and twelve or more with higher mortality.
  • Relying on a reliever also trains the wrong instinct: symptoms are suppressed quickly, so the underlying worsening goes unnoticed until an attack.
  • Overuse of beta-agonists has its own history of harm, including the asthma death epidemics in several countries in the 1960s and 1970s.

Why it matters

Needing a reliever often is not a sign that it is working. It is a warning that something else is needed.

What's still uncertain

  • Death is rare in absolute terms, which is why the pattern took large datasets to see clearly.

Read more

Next: The change

Part 3 of 5

ICS in everyone's treatment

Review of many studies

What happens

In 2019 the Global Initiative for Asthma made the most significant change to asthma treatment in thirty years.

What the research shows

  • Short-acting reliever-only treatment is no longer recommended for adolescents and adults with asthma.
  • Everyone in that group should have inhaled corticosteroid as part of their treatment, either taken daily or taken together with a reliever whenever symptoms occur.
  • The preferred approach combines a corticosteroid with formoterol, a long-acting bronchodilator that works within minutes, in a single inhaler.
  • That combination can be used as the reliever itself, so every time a person treats a symptom they also treat the inflammation that caused it.
  • In trials this reduced severe exacerbations substantially compared with reliever alone, and it did so with far less total steroid than daily dosing.

Why it matters

The elegance of the approach is that it uses the symptom as the reminder. Treating the attack and preventing the next one become the same action.

What's still uncertain

  • Uptake has been slow in many countries and many people are still on reliever-only treatment.

Read more

Next: The two tracks

Part 4 of 5

And where the US differs

Review of many studies

What happens

Guidance offers more than one route, and what is available varies by country.

What the research shows

  • Track 1 is the preferred approach: ICS-formoterol as the reliever, with or without a daily maintenance dose. Using it both ways is called MART or SMART.
  • Track 2 is an alternative for people who will not or cannot use ICS-formoterol: a daily inhaled corticosteroid with a separate short-acting reliever. It works, and adherence to a daily preventer is harder.
  • In the United States, as-needed-only ICS-formoterol for mild asthma has not been a licensed indication, which has complicated adoption. US guidance has recommended SMART for moderate asthma since 2020.
  • A combination of albuterol with budesonide in a single rescue inhaler has since been approved in the US, giving another way to deliver a steroid with every rescue dose.
  • Children under 12 are a separate question: the evidence base differs, and daily inhaled corticosteroid with a short-acting reliever remains standard in many settings.

Why it matters

If your inhaler regimen does not match what you read online, the country you are in is the most likely explanation.

What's still uncertain

  • Licensing and guideline recommendations continue to diverge between regions.

Read more

Next: What to ask

Part 5 of 5

Translating this into an appointment

Review of many studies

What happens

The practical version of everything above.

What the research shows

  • If you only have a blue reliever inhaler, ask whether your treatment should include an inhaled corticosteroid. For adolescents and adults the current answer is almost always yes.
  • If you use your reliever more than twice a week, or wake at night with symptoms, your asthma is not controlled, whatever the label on it says.
  • Ask how many reliever canisters you have used in the past year. Three or more is a signal worth acting on.
  • Ask whether you should be on a combined ICS-formoterol inhaler, and if not, why not.
  • Ask to have your inhaler technique watched. Poor technique is one of the commonest reasons treatment appears not to work, and it is fixable in five minutes.

Why it matters

Counting reliever canisters is a simple and under-used measure of risk, and most people have never been asked.

What's still uncertain

  • Changing an inhaler regimen is a clinical decision and should not be made alone.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.